Insider trading

Period: 120 months Stock: REGN + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

445 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

445 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

445 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

445 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
445 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
445 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

445 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
14 Apr 2020
STAHL NEIL EVP Research and Development
Sold, plan not stated 7×
$2.86M 5,497 at 521.07
32.6%
13 Apr 2020
Landry Robert E EVP Finance CFO
Sold, plan not stated 9×
$422.11K 828 at 509.79
3.3%
7 Apr 2020
Landry Robert E EVP Finance CFO
Sold, plan not stated 2×
$346.27K 696 at 497.52
2.8%
3 Apr 2020
Landry Robert E EVP Finance CFO
Sold, plan not stated 10×
$337.59K 683 at 494.28
2.7%
2 Apr 2020
LAROSA JOSEPH J EVP General Counsel and Secret
Sold, plan not stated 14×
$3.33M 6,797 at 489.98
32.0%
2 Apr 2020
Landry Robert E EVP Finance CFO
Sold, plan not stated 15×
$662.74K 1,353 at 489.83
5.1%
1 Apr 2020
Fenimore Christopher R. VP Controller
Sold, plan not stated 13×
$586.10K 1,200 at 488.41
8.4%
1 Apr 2020
Landry Robert E EVP Finance CFO
Sold, plan not stated 10×
$292.81K 600 at 488.02
2.4%
1 Apr 2020
RYAN ARTHUR F Director
Sold, plan not stated 18×
$48.38K 100 at 483.85
0.3%
30 Mar 2020
RYAN ARTHUR F Director
Sold, plan not stated 8×
$46.67K 100 at 466.69
0.3%
10 Mar 2020
YANCOPOULOS GEORGE President and Chief Scientific
Sold, plan not stated 25×
$55.43M 117,815 at 470.47
18.5%
9 Mar 2020
Sanofi 10% owner
Sold, plan not stated
$63.12M 128,914 at 489.65
0.6%
9 Mar 2020
Sold, plan not stated 9×
$951.68K 2,000 at 475.84
17.2%
27 Feb 2020
STAHL NEIL EVP Research and Development
Sold, plan not stated 28×
$4.68M 10,349 at 452.26
47.6%
26 Feb 2020
Van Plew Daniel P EVP & General Mgr Industrial O
Sold, plan not stated 10×
$7.15M 15,642 at 457.23
35.6%
26 Feb 2020
SING GEORGE L Director
Sold, plan not stated
$1.15M 2,500 at 460.00
2.1%
26 Feb 2020
SING GEORGE L Director · indirect
Sold, plan not stated 6×
$1.09M 2,400 at 452.83
50.0%
Sold half or more
26 Feb 2020
Landry Robert E EVP Finance CFO
Sold, plan not stated 8×
$91.24K 200 at 456.21
0.8%
25 Feb 2020
Landry Robert E EVP Finance CFO
Sold, plan not stated 10×
$96.09K 214 at 449.01
0.8%
24 Feb 2020
YANCOPOULOS GEORGE President and Chief Scientific
Sold, plan not stated
$49.63M 118,123 at 420.17
18.6%
24 Feb 2020
BROWN MICHAEL S Director
Sold, plan not stated 2×
$838.00K 2,000 at 419.00
75.7%
Sold half or more
13 Feb 2020
Sold, plan not stated 4×
$5.71M 14,279 at 400.01
88.6%
Sold half or more
13 Feb 2020
STAHL NEIL EVP Research and Development
Sold, plan not stated 5×
$4.12M 10,278 at 400.66
47.5%
13 Feb 2020
Landry Robert E EVP Finance CFO
Sold, plan not stated 6×
$42.81K 107 at 400.05
0.4%
7 Feb 2020
Sold, plan not stated
$382.83K 1,000 at 382.83
9.4%
27 Jan 2020
MURPHY ANDREW J EVP Research
Sold, plan not stated 8×
$2.73M 8,000 at 340.91
13.8%
2 Jan 2020
SING GEORGE L Director
Sold, plan not stated
$5.58M 15,000 at 371.98
11.5%
13 Dec 2019
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 7×
$19.49M 51,842 at 376.04
14.5%
13 Dec 2019
BROWN MICHAEL S Director
Sold, plan not stated 3×
$1.50M 4,000 at 373.99
92.5%
Sold half or more
13 Dec 2019
Fenimore Christopher R. VP Controller
Sold, plan not stated 5×
$632.66K 1,682 at 376.14
12.1%
27 Nov 2019
Sold, plan not stated
$370.00K 1,000 at 370.00
8.8%
26 Nov 2019
STAHL NEIL EVP Research and Development
Sold, plan not stated 3×
$1.46M 4,006 at 364.07
15.1%
25 Nov 2019
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 9×
$8.06M 22,149 at 363.87
6.8%
22 Nov 2019
Sold, plan not stated
$360.00K 1,000 at 360.00
8.8%
21 Nov 2019
Sold, plan not stated
$350.00K 1,000 at 350.00
8.8%
12 Nov 2019
BROWN MICHAEL S Director
Sold, plan not stated
$1.57M 4,500 at 349.00
93.3%
Sold half or more
8 Nov 2019
STAHL NEIL EVP Research and Development
Sold, plan not stated 10×
$2.49M 7,364 at 338.52
24.7%
8 Nov 2019
Sold, plan not stated
$340.44K 1,000 at 340.44
8.8%
10 Sep 2019
Sanofi 10% owner
Sold, plan not stated
$48.61M 172,904 at 281.15
0.8%
15 May 2019
Sold, plan not stated
$305.93K 1,000 at 305.93
8.1%
14 May 2019
STAHL NEIL EVP Research and Development
Sold, plan not stated 2×
$3.01M 9,853 at 305.74
30.5%
8 Mar 2019
Sanofi 10% owner
Sold, plan not stated
$54.04M 131,115 at 412.17
0.6%
10 Jan 2019
Sold, plan not stated
$734.31K 1,791 at 410.00
12.7%
20 Dec 2018
Fenimore Christopher R. VP Controller
Sold, plan not stated 8×
$663.38K 1,848 at 358.97
20.7%
12 Dec 2018
VAGELOS P ROY Chairman of the Board · indirect
Sold, plan not stated
$2.29K 6 at 382.32
0.3%
28 Sep 2018
Sold, plan not stated
$290.69K 709 at 410.00
5.6%
27 Sep 2018
Sold, plan not stated
$800.00K 2,000 at 400.00
14.3%
27 Sep 2018
BROWN MICHAEL S Director
Sold, plan not stated 6×
$784.52K 2,000 at 392.26
100%
Sold half or more
24 Sep 2018
Sold, plan not stated 2×
$777.29K 2,000 at 388.65
14.3%
6 Sep 2018
Sanofi 10% owner · indirect
Sold, plan not stated
$42.52M 104,552 at 406.68
0.4%
Showing 351–400 of 445. ← Newer Page 8 of 9 Older →